BioMarin PharmaceuticalsBMRN
Market Cap: 16.1B
About: BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Employees: 3,401
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
7% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 59
1% more funds holding
Funds holding: 527 [Q4 2023] → 531 (+4) [Q1 2024]
5% less repeat investments, than reductions
Existing positions increased: 186 | Existing positions reduced: 195
1.41% less ownership
Funds ownership: 98.24% [Q4 2023] → 96.83% (-1.41%) [Q1 2024]
11% less capital invested
Capital invested by funds: $17.8B [Q4 2023] → $16B (-$1.89B) [Q1 2024]
19% less call options, than puts
Call options by funds: $181M | Put options by funds: $222M
57% less funds holding in top 10
Funds holding in top 10: 14 [Q4 2023] → 6 (-8) [Q1 2024]
Research analyst outlook
16 Wall Street Analysts provided 1 year price forecasts over the past 6 months
16 analyst ratings
Canaccord Genuity Whitney Ijem | 5%upside $89 | Hold Maintained | 25 Jul 2024 |
Cantor Fitzgerald Olivia Brayer | 30%upside $110 | Overweight Reiterated | 22 Jul 2024 |
Wells Fargo Mohit Bansal | 36%upside $115 | Overweight Maintained | 27 Jun 2024 |
Baird Joel Beatty | 15%downside $72 | Neutral Downgraded | 17 May 2024 |
Evercore ISI Group Cory Kasimov | 34%upside $113 | Outperform Initiated | 14 May 2024 |
Financial journalist opinion
Based on 5 articles about BMRN published over the past 30 days